Relationships Between Clinical Scales and Binge Eating Days in Adults with Moderate to Severe Binge Eating Disorder in Two Phase III Studies by Citrome, Leslie L et al.
Touro Scholar 
NYMC Faculty Publications Faculty 
2-1-2018 
Relationships Between Clinical Scales and Binge Eating Days in 
Adults with Moderate to Severe Binge Eating Disorder in Two 
Phase III Studies 
Leslie L. Citrome 
New York Medical College 
Judith C. Kando 
Caleb Bliss 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs 
 Part of the Psychiatry and Psychology Commons, and the Therapeutics Commons 
Recommended Citation 
Citrome, L. L., Kando, J., & Bliss, C. (2018). Relationships Between Clinical Scales and Binge Eating Days 
in Adults with Moderate to Severe Binge Eating Disorder in Two Phase III Studies. Neuropsychiatric 
Disease and Treatment, 14, 537-546. https://doi.org/10.2147/NDT.S158395 
This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for 
inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, 
please contact touro.scholar@touro.edu. 
© 2018 Citrome et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Neuropsychiatric Disease and Treatment 2018:14 537–546
Neuropsychiatric Disease and Treatment Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
537
O r i g i N a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/NDT.S158395
relationships between clinical scales and binge 
eating days in adults with moderate to severe 




1Department of Psychiatry and 
Behavioral sciences, New York 
Medical college, Valhalla, NY, Usa; 
2shire, global Medical affairs, 
lexington, Ma, Usa; 3shire, 
Biostatistics, lexington, Ma, Usa
Objectives: In two Phase III studies, lisdexamfetamine dimesylate (LDX) reduced binge 
eating (BE) days/week in adults with moderate to severe binge eating disorder (BED) and was 
associated with improvement based on the Clinical Global Impressions–Improvement (CGI-I) 
scale. In this study, post hoc analyses examined the relationships between clinical observations 
and clinical rating scales in individuals with BED.
Clinical trial registration: NCT01718483 (ClinicalTrials.gov/ct2/show/NCT01718483); 
NCT01718509 (ClinicalTrials.gov/ct2/show/NCT01718509).
Methods: Two 12-week, double-blind, placebo-controlled studies randomized (1:1) adults 
meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, 
BED criteria and with protocol-defined moderate to severe BED (study 1, N=383; study 2, 
N=390) to placebo or dose-optimized LDX (50 or 70 mg). Assessments included the number of 
BE days/week, CGI–Severity (CGI-S) and CGI-I scores, and Yale-Brown Obsessive Compulsive 
Scale modified for Binge Eating (Y-BOCS-BE) total scores. For these post hoc analyses, data 
were pooled across studies and treatment arms. Statistical assessments included Spearman corre-
lations and equipercentile linking analyses (ELA). Reported P-values are nominal (descriptive 
and not adjusted for multiplicity).
Results: At baseline, nominally significant correlations with CGI-S scores were reported for 
BE days/week (r=0.374; P,0.0001) and Y-BOCS-BE total scores (r=0.319; P,0.0001). Base-
line ELA for CGI-S further characterized this relationship: a CGI-S score of 4 (moderately ill) 
corresponding to 3.504 BE days/week and a Y-BOCS-BE total score of 18.6. Nominally 
significant correlations with CGI-I scores were reported for changes from baseline at study 
endpoint for BE days/week (r=0.647; P,0.0001) and Y-BOCS-BE total scores (r=0.741; 
P,0.0001). ELA for CGI-I scores at study endpoint showed that a CGI-I score of 1 (very much 
improved) corresponds to a reduction from baseline of 4.504 BE days/week and 19.4 points 
for Y-BOCS-BE total score.
Conclusion: These post hoc analyses suggest that indices of global disease severity and improve-
ment positively correlate with BE behavior and with obsessive and compulsive features of BED, 
measured by the Y-BOCS-BE, supporting the clinical relevance of BED treatment outcomes.
Keywords: binge eating days, binge eating disorder, lisdexamfetamine dimesylate, clinical 
rating scales, Clinical Global Impressions scale, Yale-Brown Obsessive Compulsive Scale 
modified for Binge Eating
Plain language summary
Lisdexamfetamine dimesylate (LDX) reduced binge eating days/week, reduced the obsessiveness 
of binge eating thoughts and compulsiveness of binge eating behavior (based on the Yale-Brown 
Obsessive Compulsive Scale modified for Binge Eating [Y-BOCS-BE]), and produced global 
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disease improvement (based on the Clinical Global Impressions–
Improvement [CGI-I] scale) in adults with moderate to severe binge 
eating disorder (BED) in Phase III clinical studies. In the present 
study, pooled, post hoc analyses examined the relationships between 
clinical observations (binge eating days/week and Y-BOCS-BE 
total score) and clinical rating scales (CGI–Severity [CGI-S] and 
CGI-I) in individuals with BED who participated in two LDX clini-
cal studies using equipercentile linking analyses. The findings from 
these analyses suggest that global disease severity and improvement 
measures (the CGI-S and CGI-I, respectively) positively correlate 
with binge eating frequency, with the obsessiveness of binge eating 
thoughts, and with the compulsiveness of binge eating behavior 
(measured with Y-BOCS-BE total score). Additionally, binge eating 
frequency reductions of 3.5–7.0 days/week and Y-BOCS-BE total 
score reductions of 13.9–36.5 points correspond to CGI-I scores of 
“very much improved”. These findings support the clinical relevance 
of treatment outcomes in BED.
Introduction
Lisdexamfetamine dimesylate (LDX) is approved for use in 
adults with moderate to severe binge eating disorder (BED) in 
the US1 and other countries. In two large Phase III, random-
ized, double-blind, placebo-controlled trials, LDX resulted 
in clinically meaningful and statistically significant reduc-
tions in binge eating (BE) days/week compared with placebo 
in adults with protocol-defined moderate to severe BED.2 
In these studies, the least squares mean (95% CI) treatment 
differences for the change from baseline BE days/week at 
weeks 11–12 significantly favored LDX over placebo (study 
1: -1.35 [-1.70, -1.01]; study 2: -1.66 [-2.04, -1.28]; both 
P,0.001).2
In these studies, LDX also produced statistically sig-
nificant improvements on key secondary endpoints that 
included the Clinical Global Impressions–Improvement 
(CGI-I) scale and the Yale-Brown Obsessive Compulsive 
Scale modified for Binge Eating (Y-BOCS-BE).2 On the 
dichotomized CGI-I, the percentage of participants catego-
rized as improved (those with scores of 1 or 2 [much/very 
much improved]) at week 12/early termination (ET) was 
greater with LDX than with placebo (study 1: 82.1% vs 
47.3%; study 2: 86.2% vs 42.9%; both P,0.001),2 resulting 
in a pooled number needed to treat of 3 (95% CI: 3–4) for 
LDX versus placebo.3 For Y-BOCS-BE total score, the least 
squares mean (95% CI) treatment differences for change from 
baseline at week 12 significantly favored LDX over placebo 
(study 1: -7.40 [-8.93, -5.88]; study 2: -7.94 [-9.51, -6.36]; 
both P,0.001).2
In both studies,2 the safety and tolerability profile of LDX 
was consistent with its well-established profile in individuals 
with attention-deficit/hyperactivity disorder (ADHD).1 
Treatment-emergent adverse events reported by $10% 
of participants treated with LDX in both studies were dry 
mouth, insomnia, and headache.2 The observed increases in 
blood pressure and heart rate2 were also consistent with the 
established safety profile of LDX in ADHD.1
Relationships between global clinical disease severity and 
improvement (measured with the CGI–Severity [CGI-S] and 
CGI-I scales), the number of BE days/week, and Y-BOCS-BE 
total score in individuals with BED have not previously been 
described. Such analyses are key to our understanding of the 
clinical significance of specific observations (eg, reductions 
in BE days/week or Y-BOCS-BE total score) in individuals 
with BED by relating them to standardized global clinical 
rating scales (ie, CGI-S or CGI-I) that are used in studies of 
a wide range of psychiatric disorders.
Similar types of analyses have been conducted in other 
psychiatric conditions, including ADHD, schizophrenia, 
and panic disorder.4–7 In an analysis of two LDX studies 
in individuals with ADHD (one in children8 and one in 
adults9), the relationship between ADHD Rating Scale, 
Version 4 (ADHD-RS-IV) total scores and CGI-S and 
CGI-I scores was examined.4 This post hoc analysis found 
that ADHD-RS-IV total score changes from baseline 
of ~8–10 points corresponded to a 1-point improvement in 
CGI-S score and that changes of 10–15 points corresponded 
to a 1-point improvement in CGI-I score.4 In an analysis of 
14 clinical trials of acutely ill individuals with schizophrenia,7 
relationships between the Brief Psychiatric Rating Scale 
(BPRS), Positive and Negative Syndrome Scale (PANSS), 
and CGI-I scores were examined. This analysis demon-
strated that 10-point reductions on the BPRS and 15-point 
reductions on the PANSS corresponded to a CGI-I rating of 
minimally improved and a CGI-S score change of 1 point.7 
Taken together, these analyses support the concept that the 
CGI is a valid estimate of psychopathology and clinically 
relevant disease improvement, thereby offering the practicing 
clinician a tool to track global disease improvement during 
treatment, as has previously been suggested.10,11
The objective of this report was to further understand 
the relationships between clinical observations of BE, the 
number of BE days/week and Y-BOCS-BE total score, and 
the CGI-S at baseline and the CGI-I at the end of treatment 
in adults with BED.
Methods
The design and methodology of the two Phase III BED 
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relationships between clinical observations and rating scales in BeD
been described in detail;2 a summary is provided in the fol-
lowing text.
study design and treatment
These randomized, placebo-controlled, parallel-group, 
multicenter studies (ClinicalTrials.gov registry numbers: 
NCT01718483 and NCT01718509) were conducted using 
the same design and methods. Each study included three 
phases: a 2-week screening phase, a 12-week double-blind 
phase (dose-optimization period, 4 weeks; dose-maintenance 
period, 8 weeks), and a follow-up visit. After screening, par-
ticipants were randomized 1:1 to placebo or dose-optimized 
LDX (50 or 70 mg) for 12 weeks. Treatment with LDX was 
started at 30 mg during week 1 and increased to 50 mg during 
week 2. Increases to 70 mg LDX, based on tolerability and 
clinical need, occurred during weeks 3 and 4. A one-time 
decrease to 50 mg LDX was permitted during week 3 based 
on participant tolerability. The optimized LDX dosage (50 or 
70 mg) was maintained during weeks 4–12; participants 
requiring a dosage reduction during the dose-maintenance 
phase were discontinued. A follow-up visit occurred 1 week 
after the week 12/ET visit to assess safety.
Each study was approved by ethics committees (Box S1). 
Both studies were conducted in accordance with International 
Conference on Harmonization of Good Clinical Practice and 
the principles of the Declaration of Helsinki. All participants 
were required to provide written, informed consent before 
entering a study.
Participants
Eligible participants were men or nonpregnant women (aged 
18–55 years) meeting Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revision (DSM-
IV-TR) BED criteria, confirmed by the eating disorders 
module of the Structured Clinical Interview for the DSM-IV 
Axis I Disorders and the Eating Disorder Examination 
Questionnaire, and having protocol-defined moderate to 
severe BED ($3 BE days/week for 14 days before base-
line and a CGI-S score $4 at screening and baseline) and 
a body mass index (BMI) of 18–45 kg/m2. Full exclusion 
criteria have been reported previously.2 Key exclusion 
criteria included current anorexia nervosa or bulimia 
nervosa; a comorbid psychiatric disorder controlled with 
prohibited medications or uncontrolled and associated with 
significant symptoms or any condition that could confound 
assessments; having received psychotherapy or weight 
loss support for BED within 3 months of screening; being 
considered a suicide risk by the investigator, previously 
attempting suicide, or currently demonstrating active sui-
cidal ideation; having a history of cardiovascular issues 
or moderate or severe hypertension; and having a lifetime 
amphetamine or stimulant abuse history, recent substance 
abuse or dependence history, or intolerance or hypersensi-
tivity to LDX or related compounds. Excluded medications 
included benzodiazepines, antidepressants, antipsychotics, 
anxiolytics, clonidine, guanfacine, investigational com-
pounds, monoamine oxidase inhibitors, narcotics, sedatives/
sedative hypnotics, weight loss therapies (within 30 days of 
screening); sympathomimetics and appetite suppressants 
(within 6 months of screening); and cough/cold suppressants 
containing stimulants/sympathomimetic agents, herbal prep-
arations, melatonin, sedating antihistamines (within 7 days 
of screening). In addition, any psychoactive medication used 
within five half-lives of screening was exclusionary.
endpoints
Efficacy endpoints included in these post hoc analyses 
included BE days/week, CGI-S and CGI-I scores, and 
Y-BOCS-BE total score. BE days/week (prespecified primary 
efficacy endpoint) was captured daily via self-reported 
diaries. The CGI-S assessed global disease severity at base-
line on a 7-point scale (range: 1 [normal, not at all ill] to 7 
[among the most extremely ill]).12 The CGI-I (prespecified 
key secondary endpoint), a measure of global improvement 
in disease severity12 relative to baseline, was assessed on a 
7-point scale (range: 1 [very much improved] to 7 [very much 
worse]). The Y-BOCS-BE13 (prespecified key secondary 
endpoint), which is a modified version of the Y-BOCS,14 
assessed the obsessiveness of BE thoughts and compulsive-
ness of BE behavior. Y-BOCS-BE total score ranges from 
0 to 40, with higher scores indicating more severe symptoms.
Data presentation and statistical analyses
For the post hoc analyses described herein, data at baseline or 
study endpoint (weeks 11–12 for BE days/week; week 12/ET 
for CGI-I; week 12 for Y-BOCS-BE total score) were pooled 
across studies. Data are reported for each treatment arm and 
for the overall population. Participants were from the full 
analysis set (FAS; those taking $1 study drug dose and 
having $1 postbaseline assessment for the number of BE 
days/week) of each study with non-missing values for both 
variables in each relationship.
Descriptive statistics for BE days/week and Y-BOCS-BE 
total score are presented by CGI-S and CGI-I scores. Spearman 
correlations assessed relationships at baseline (CGI-S 
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Y-BOCS-BE total score) and at study endpoint (CGI-I score 
at week 12/ET and the number of BE days/week at weeks 
11–12; CGI-I score at week 12/ET and the change from 
baseline in the number of BE days/week at weeks 11–12; 
CGI-I score at week 12/ET and Y-BOCS-BE total score 
at week 12; CGI-I score at week 12/ET and the change in 
Y-BOCS-BE total score at week 12). Reported P-values are 
nominal (ie, not adjusted for multiplicity) and are presented 
for descriptive purposes only.
Equipercentile linking analyses were conducted as previ-
ously described by Goodman et al.4 These analyses identified 
scores on different measures with the same percentile rank. 
First, a percentile rank function for each variable was gener-
ated. For each function, respective scores on two measures 
were plotted as X, Y pair values based on each variable 
having the same percentile rank. Percentile rank functions 
were calculated for relationships at baseline (CGI-S score and 
the number of BE days/week; CGI-S score and Y-BOCS-BE 
total score) and at study endpoint (CGI-I score at week 12/ET 
and the change from baseline in the number of BE days/week 
at weeks 11–12; CGI-I score at week 12/ET and the change 
in Y-BOCS-BE total score at week 12). The equipercentile 
linking function requires that both variables be continuous. 
To apply this method in the current analyses, CGI-S, CGI-I, 
and Y-BOCS-BE scores were considered piecewise continu-
ous in the range X -0.5 to X +0.5, and BE days/week values 
were considered piecewise continuous in the range X -0.005 
to X +0.005 (as shown in Figure 1). Therefore, all reported 
values are understood to encompass a range. It is important 
to emphasize that this technique did not compare absolute 
scores between measures for individual participants. Rather, 
it identified scores for clinical observations (BE days/week or 
Y-BOCS-BE) having the same percentile rank on a clinical 
scale (CGI-S or CGI-I). Individual participant scores on spe-
cific items on the Y-BOCS-BE were not taken into account.
Results
Participant disposition and demographics
The pooled FAS in this analysis included 360 participants 
randomized to placebo and 364 randomized to LDX. 
Participant demographic and clinical characteristics are 
briefly summarized in Table 1. Most participants were female, 
white, and obese (BMI range: 18.5–45.2 kg/m2). The mean 
number of BE days/week, mean Y-BOCS-BE total score, 
Figure 1 equipercentile linking functionsa at baseline (A and B) and for change from baseline (C and D), pooled full analysis set.
Notes: aThe equipercentile linking function requires that both variables be continuous. To apply this method, scores for cgi-s, cgi-i, and Y-BOcs-Be were considered 
piecewise continuous ranging from X -0.5 to X +0.5, and scores for binge eating days/week were considered piecewise continuous ranging from X -0.005 to X +0.005. 
Therefore, all values are understood to encompass a range.
Abbreviations: Be, binge eating; cgi-i, clinical global impressions–improvement; cgi-s, clinical global impressions–severity; eT, early termination; lDX, lisdexamfetamine 
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relationships between clinical observations and rating scales in BeD
and distribution of CGI-S scores at baseline were comparable 
across treatment groups.
score distributions
Baseline BE days/week and Y-BOCS-BE total scores by 
CGI-S score, values at the end of the study by CGI-I score, 
and changes from baseline at the end of the study by CGI-I 
score are summarized in Table 2.
Baseline relationships
Nominally significant correlations with CGI-S scores 
were reported for the number of BE days/week (r=0.374; 
P,0.0001) and Y-BOCS-BE total score (r=0.319; P,0.0001; 
Table 2) in the overall population, with a higher number of 
BE days/week and higher Y-BOCS-BE total scores at base-
line being associated with higher baseline CGI-S scores. For a 
CGI-S score of 4 (moderately ill) at baseline, the mean ± SD 
number of BE days/week at baseline was 4.27±1.130 and the 
mean ± SD Y-BOCS-BE total score was 20.06±3.967 in the 
overall population (Table 2).
Equipercentile linking functions for CGI-S scores and 
BE days/week and Y-BOCS-BE total score at baseline are 
depicted in Figure 1A and B. In the overall population, a 
CGI-S score of 4 (moderately ill) corresponded to 3.504 
(range: 1.995–4.501) BE days/week and a Y-BOCS-BE total 
score of 18.6 (range: 7.5–21.6; Table 3).
change from baseline relationships
Nominally significant correlations with CGI-I scores 
were reported for the number of BE days/week (r=0.795; 
P,0.0001), for the change from baseline in BE days/week 
at weeks 11–12 (r=0.647; P,0.0001), for Y-BOCS-BE 
total score at week 12 (r=0.797; P,0.0001), and for the 
change from baseline in Y-BOCS-BE total score at week 12 
(r=0.741; P,0.0001; Table 2) in the overall population; 
a lower number of BE days/week and greater reductions 
from baseline were associated with greater improvement as 
measured by the CGI-I. For the placebo and LDX treatment 
groups, respectively, nominally significant correlations with 
CGI-I scores were reported for the number of BE days/week 
(r=0.764 and r=0.668; both P,0.0001), for the change from 
baseline in BE days/week at weeks 11–12 (r=0.695 and 
r=0.391; both P,0.0001), for Y-BOCS-BE total score at 
week 12 (r=0.726 and r=0.671; both P,0.0001), and for the 
change from baseline in Y-BOCS-BE total score at week 12 
(r=0.695 and r=0.560; both P,0.0001).
For a CGI-I score of 1 (very much improved) at 
week 12/ET, the mean ± SD number of BE days/week at 
weeks 11–12 was 0.26±0.523 in the overall population, 
0.33±0.620 in the placebo treatment group, and 0.23±0.481 
in the LDX treatment group; the mean ± SD change in BE 
days/week from baseline was -4.36±1.384 in the overall 
population, -4.27±1.522 in the placebo treatment group, 
and -4.39±1.331 in the LDX treatment group (Table 2). For 
Y-BOCS-BE total score, the mean ± SD total score at week 12 
was 3.05±3.951 in the overall population, 4.47±4.585 in the 
placebo treatment group, and 2.53±3.565 in the LDX treat-
ment group in participants with a CGI-I score of 1 at week 
12/ET; the mean ± SD change from baseline in total score 
was -18.39±6.129 in the overall population, -17.35±7.189 in 
the placebo treatment group, and -18.77±5.661 in the LDX 
treatment group (Table 2).
Equipercentile linking functions between CGI-I scores 
and changes in the number of BE days/week and Y-BOCS-BE 
total score are depicted in Figure 1C and D. In the overall 
population, a CGI-I score of 1 (very much improved) at 
week 12/ET corresponded to a change of -4.504 (range: -7.005 
to -3.502; Table 3) from baseline in the number of BE days/
week at weeks 11–12. For the placebo and LDX treatment 
groups, respectively, a CGI-I score of 1 at week 12/ET cor-
responded to changes of -4.996 (range: -7.005 to -3.997) 
and -4.502 (range: -7.005 to -3.498) from baseline in 








Mean ± sD age, years 38.0±10.18 38.1±10.12 37.9±10.25
Female, n (%) 627 (86.6) 310 (86.1) 317 (87.1)
White, n (%) 550 (76.0) 274 (76.1) 276 (75.8)
Mean ± sD weight, kg 93.67±20.223 93.00±19.832 94.33±20.608
BMia
Mean ± sD, kg/m2 33.52±6.254 33.32±6.292 33.72±6.218
Obese (BMi 
$30 kg/m2), n (%)
495 (68.4) 247 (68.6) 248 (68.1)




Moderately ill 381 (52.6) 183 (50.8) 198 (54.4)
Markedly ill 280 (38.7) 141 (39.2) 139 (38.2)
severely ill 56 (7.7) 34 (9.4) 22 (6.0)
among the most 
extremely ill
7 (1.0) 2 (0.6) 5 (1.4)
Mean ± sD Y-BOcs-
Be total scorec
21.49±4.724 21.52±4.785 21.46±4.669
Notes: aParticipants with BMi ,18.5 kg/m2 were not enrolled. bBased on inclusion 
criteria, a cgi-s score $4 (at least moderately ill) was required for study eligibility. 
cBased on n=721 for the overall population, n=359 for placebo and n=362 for lDX.
Abbreviations: Be, binge eating; BMi, body mass index; cgi-s, clinical global 
impressions–severity; lDX, lisdexamfetamine dimesylate; PBO, placebo; Y-BOcs-






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Table 2 Binge eating days/week and Y-BOcs-Be total score distribution by cgi-s and cgi-i scores, pooled full analysis set 
Overall PBO LDX
n Mean ± SD n Mean ± SD n Mean ± SD
Baseline values
CGI-S at baseline Binge eating days/week
Moderately ill (cgi-s =4) 381 4.27±1.130 183 4.20±1.144 198 4.33±1.117
Markedly ill (cgi-s =5) 280 5.12±1.273 141 5.18±1.300 139 5.06±1.246
severely ill (cgi-s =6) 56 5.56±1.245 34 5.42±1.215 22 5.77±1.288
among the most extremely ill (cgi-s =7) 7 6.07±1.592 2 5.25±2.475 5 6.40±1.342
spearman correlations n=724; r=0.374; P,0.0001 n=360; r=0.389; P,0.0001 n=364; r=0.359; P,0.0001
CGI-S at baseline Y-BOCS-BE total score
Moderately ill (cgi-s =4) 380 20.06±3.967 183 20.05±3.738 197 20.06±4.179
Markedly ill (cgi-s =5) 278 22.72±4.687 140 22.48±4.716 138 22.96±4.662
severely ill (cgi-s =6) 56 24.46±5.818 34 24.82±6.379 22 23.91±4.918
among the most extremely ill (cgi-s =7) 7 27.00±6.429 2 32.50±9.192 5 24.80±4.438
spearman correlations n=721; r=0.319; P,0.0001 n=359; r=0.318; P,0.0001 n=362; r=0.319; P,0.0001
End of study values
CGI-I at week 12/ET Binge eating days/week (weeks 11–12)
Very much improved (cgi-i =1) 270 0.26±0.523 73 0.33±0.620 197 0.23±0.481
Much improved (cgi-i =2) 130 1.33±1.198 62 1.44±1.198 68 1.24±1.199
Minimally improved (cgi-i =3) 87 2.66±1.627 63 2.81±1.726 24 2.26±1.280
No change (cgi-i =4) 114 3.98±1.835 99 4.05±1.816 15 3.51±1.958
Minimally worse (cgi-i =5) 5 5.63±1.488 5 5.63±1.488 0 –
spearman correlations n=606; r=0.795; P,0.0001 n=302; r=0.764; P,0.0001 n=304; r=0.668; P,0.0001
CGI-I at week 12/ET Y-BOCS-BE total score (week 12)
Very much improved (cgi-i =1) 276 3.05±3.951 74 4.47±4.585 202 2.53±3.565
Much improved (cgi-i =2) 131 9.86±5.320 62 11.16±5.463 69 8.70±4.942
Minimally improved (cgi-i =3) 89 15.78±6.376 63 17.27±6.120 26 12.15±5.562
No change (cgi-i =4) 118 19.34±5.735 102 19.49±5.712 16 18.38±5.976
Minimally worse (cgi-i =5) 5 18.60±2.702 5 18.60±2.702 0 –
spearman correlations n=619; r=0.797; P,0.0001 n=306; r=0.726; P,0.0001 n=313; r=0.671; P,0.0001
Change from baseline values
CGI-I at week 12/ET Binge eating days/week (weeks 11–12)
Very much improved (cgi-i =1) 270 -4.36±1.384 73 -4.27±1.522 197 -4.39±1.331
Much improved (cgi-i =2) 130 -3.41±1.503 62 -3.30±1.540 68 -3.51±1.472
Minimally improved (cgi-i =3) 87 -2.10±1.512 63 -1.93±1.622 24 -2.53±1.085
No change (cgi-i =4) 114 -0.88±1.739 99 -0.68±1.591 15 -2.16±2.158
Minimally worse (cgi-i =5) 5 -0.47±1.980 5 -0.47±1.980 0 –
spearman correlations n=606; r=0.647; P,0.0001 n=302; r=0.695; P,0.0001 n=304; r=0.391; P,0.0001
CGI-I at week 12/ET Y-BOCS-BE total score (week 12)
Very much improved (cgi-i =1) 275 -18.39±6.129 74 -17.35±7.189 201 -18.77±5.661
Much improved (cgi-i =2) 130 -11.56±6.258 62 -9.94±6.222 68 -13.04±5.956
Minimally improved (cgi-i =3) 89 -5.24±5.881 63 -4.11±5.728 26 -7.96±5.429
No change (cgi-i =4) 118 -2.69±5.328 102 -2.10±4.948 16 -6.44±6.261
Minimally worse (cgi-i =5) 5 -0.40±1.673 5 -0.40±1.673 0 –
spearman correlations n=617; r=0.741; P,0.0001 n=306; r=0.695; P,0.0001 n=311; r=0.560; P,0.0001
Abbreviations: cgi-i, clinical global impressions–improvement; cgi-s, clinical global impressions–severity; eT, early termination; lDX, lisdexamfetamine dimesylate; 
PBO, placebo; Y-BOCS-BE, Yale-Brown Obsessive Compulsive Scale modified for Binge Eating. 
BE days/week at weeks 11–12. In the overall population, a 
CGI-I score of 1 at week 12/ET corresponded to a change 
of -19.4 (range: -36.5 to -13.9; Table 3) from baseline in 
Y-BOCS-BE total score at week 12. For the placebo and 
LDX treatment groups, respectively, a CGI-I score of 1 at 
week 12/ET corresponded to changes of -18.4 (range: -36.5 
to -14.1) and -19.7 (range: -31.5 to -13.9) from baseline in 
Y-BOCS-BE total score at week 12.
Discussion
These post hoc analyses indicate that measures of global 
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relationships between clinical observations and rating scales in BeD
CGI-I) positively correlate with BE frequency (reflected by 
the number of BE days/week) and with the obsessive and 
compulsive features of BED (reflected by Y-BOCS-BE total 
score). These findings in individuals with BED are consis-
tent with those reported in analogous analyses conducted 
with individuals with ADHD, schizophrenia, and panic 
disorder.4–7
These findings provide a benchmark for the interpreta-
tion of the clinical relevance of values for BE days/week and 
Y-BOCS-BE total score (in regard to global disease severity 
based on CGI-S scores) and reductions in BE days/week 
and Y-BOCS-BE total scores (in regard to global clinical 
improvement based on CGI-I scores). At baseline, values 
for the number of BE days/week and Y-BOCS-BE total 
score that corresponded to “moderately ill” on the CGI-S 
were 3.504 and 18.6, respectively. The value of 18.6 for 
Y-BOCS-BE total score is consistent with the suggestion 
that Y-BOCS-BE total scores in the range 16–23 cor-
respond to the moderate symptom range.15 At the end of 
the study, reductions in the number of BE days/week and 
in Y-BOCS-BE total score corresponding to “very much 
improved” on the CGI-I were -4.504 and -19.4, respectively. 
The Y-BOCS-BE changes associated with “minimally 
improved” (-5.2) to “very much improved” (-19.4) on the 
CGI-I are roughly consistent with the reported minimally 
clinically important change of -4 to -17 for the Y-BOCS-
BE.13 Although multiple studies have reported concurrent 
reductions in BE frequency, Y-BOCS-BE total score, and 
CGI-S score, and global disease improvement on the CGI-I 
in adults with BED following pharmacologic treatment,16–20 
none of these studies described the relationships between 
these measures at baseline or at study endpoint. As such, 
the current analyses are novel and help place baseline BE 
frequency and Y-BOCS-BE total scores, as well as changes 
in these measures, in a clinical context.
It is important to note that wide score ranges were observed 
on both CGI-I (0–7 at week 12/ET) and Y-BOCS-BE (8–39 
points at baseline; 1-point increase to -36-point reductions 
at week 12). This variability may reflect the many different 
inputs that comprise the evaluation of an individual on these 
scales. For example, in clinical assessments, differing base-
line levels of severity and BE frequency among individuals 
will result in differing determinations of what constitutes a 
response that is “very much improved” or “much improved” 









CGI-S at baselineb n=724 n=360 n=364
Moderately ill (cgi-s =4) 3.504 (1.995, 4.501) 3.503 (1.995, 4.499) 3.995 (1.995, 4.503)
Markedly ill (cgi-s =5) 5.501 (4.502, 6.997) 5.499 (4.500, 6.996) 5.503 (4.503, 6.998)
severely ill/extremely ill (cgi-s =6 or 7)c 7.001/7.005 (6.997, 7.005) 7.000/7.005 (6.996, 7.005) 7.001/7.004 (6.998, 7.005)
CGI-I at week 12/ET n=606 n=302 n=304
Very much improved (cgi-i =1) -4.504 (-7.005, -3.502) -4.996 (-7.005, -3.997) -4.502 (-7.005, -3.498)
Much improved (cgi-i =2) -3.003 (-3.502, -2.500) -3.420 (-3.996, -2.628) -2.997 (-3.498, -2.310)
Minimally improved (cgi-i =3) -1.996 (-2.499, -1.497) -1.997 (-2.624, -1.498) -1.995 (-2.303, -1.495)
Not improved (cgi-i =4 or 5)d -0.305/1.922 (-1.496, 3.005) -0.004/1.922 (-1.497, 3.005) -0.540/Na (-1.269, 0.505)
Y-BOCS-BE total scorea
CGI-S at baselineb n=721 n=359 n=362
Moderately ill (cgi-s =4) 18.6 (7.5, 21.6) 18.3 (7.5, 21.2) 19.1 (7.5, 22.0)
Markedly ill (cgi-s =5) 24.0 (21.6, 28.0) 23.7 (21.2, 27.7) 24.4 (22.0, 28.2)
severely ill/extremely ill (cgi-s =6 or 7)c 29.7/35.2 (28.1, 39.5) 29.9/36.5 (27.8, 39.5) 29.5/32.1 (28.3, 37.5)
CGI-I at week 12/ET n=617 n=306 n=311
Very much improved (cgi-i =1) -19.4 (-36.5, -13.9) -18.4 (-36.5, -14.1) -19.7 (-31.5, -13.9)
Much improved (cgi-i =2) -11.0 (-13.8, -7.8) -10.8 (-14.0, -7.6) -11.3 (-13.8, -7.9)
Minimally improved (cgi-i =3) -5.2 (-7.7, -2.9) -4.9 (-7.6, -2.8) -5.6 (-7.9, -2.9)
Not improved (cgi-i =4 or 5)d -0.0/6.7 (-2.8, 10.5) 0.1/6.7 (-2.8, 10.5) -0.8/Na (-2.7, 3.5)
Notes: aBaseline values for cgi-s analysis; values at week 11/12 for binge days/week and week 12 for Y-BOcs-Be total score for cgi-i analysis. bestimates for cgi-s scores 
of 1 (normal, not at all ill), 2 (borderline mentally ill), and 3 (mildly ill) could not be determined because inclusion criteria for the studies required a cgi-s score $4. cFor 
the current analyses, scores of 6 (severely ill) or 7 (most extremely ill) on the cgi-s were merged because of limited sample size. dFor the current analyses, scores of 4 or 5 
(no participants had scores of 6 or 7) on the CGI-I were merged because of limited sample size and defined as “not improved”.
Abbreviations: cgi-i, clinical global impressions–improvement; cgi-s, clinical global impressions–severity; eT, early termination; lDX, lisdexamfetamine dimesylate; 
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on the CGI-I. Moreover, if BE behaviors are markedly 
reduced but the obsessive thoughts about BE persist, the 
overall CGI-I would also be affected.
When interpreting these analyses, several limitations 
should be considered. First, these are post hoc analyses based 
on pooled data from two studies. Therefore, the reported 
P-values are nominal (ie, not adjusted for multiplicity) and 
should be interpreted with caution. Furthermore, although by 
convention CGI-S scores .3 denote some level of functional 
impairment,11 using the CGI-S as the sole proxy for clinical 
severity could limit the precision of the findings because 
specific indices of functional impairment are not taken into 
account. Potential ceiling effects could also influence the 
data because relatively few participants were categorized as 
“severely ill” or “among the most severely ill” on the CGI-S 
at baseline. Similarly, potential floor effects could influence 
the data because study entry required a BE frequency $3 
BE days/week and a CGI-S score $4 at baseline. Lastly, 
a detailed examination of the Y-BOCS-BE subscales was 
not conducted because the intent of these analyses was to 
demonstrate broad relationships between total score on a 
research rating scale, observed behaviors, and general clinical 
impressions. The approach followed in these analyses is 
consistent with previous examinations in other psychiatric 
disorders.4–7 A detailed component analysis of LDX treat-
ment effects is beyond the scope of this paper, but would be 
of interest to pursue in the future.
Conclusions
The CGI is a scale that allows clinicians to capture more 
information than is captured by BE frequency or by means 
of binge-related obsessive thoughts and compulsive behav-
iors. Specifically, it allows clinicians to consider the distress 
level and level of functional impairment of an individual.11 
These factors are not always captured in formal rating scales, 
making the CGI an important secondary assessment in 
clinical studies. The current post hoc analyses in individuals 
with protocol-defined moderate to severe BED suggest that 
CGI-S score (an index of global disease severity) positively 
correlates with baseline levels of BE behavior and with 
the obsessive and compulsive features of BED, with the 
equipercentile linking function demonstrating that a CGI-S 
score of 4 (moderately ill) corresponds to 1.995–4.501 BE 
days/week and to a Y-BOCS-BE total score of 7.5–21.6. 
Furthermore, the analyses suggest that CGI-I score (an index 
of global disease improvement) positively correlates with 
reductions in the same measures, with the equipercentile 
linking function demonstrating that a CGI-I score of 1 (very 
much improved) corresponds to a decrease in BE days/week 
ranging from 3.502 to 7.005 and to a decrease in Y-BOCS-BE 
total score ranging from 13.9 to 36.5 points. Taken together, 
these observations further improve our understanding of the 
clinical significance of treatment outcomes in BED.
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